BAAR, Switzerland--(BUSINESS WIRE)--May 4, 2006--Biopartners, a privately-owned biopharmaceuticals company has received marketing authorisation for the European Union from the European Commission for its biosimilar medicinal product Valtropin, a recombinant human growth hormone used for the treatment of human growth deficiency in children and Turner's Syndrome. This is only the second biosimilar product to receive EU marketing authorisation from the European Commission and confirms Biopartners' position as a leader in the development of biosimilars. Biopartners, jointly with LG Life Sciences, has co-developed a number of biopharmaceutical products including Valtropin and a sustained release formulation of Valtropin. Biopartners in-licensed Valtropin from LG Life Sciences and has commercialization rights for Valtropin in Europe, Japan and other parts of Asia.
